All In Biotech

Drug Trial Radar · NCT07774520

A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemptive Magnesium Supplementation to Prevent Lazertinib (Leclaza)-Induced Peripheral Neuropathy

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,173 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,173

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

Jun 1, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Lazertinib is currently approved as a first-line treatment for EGFR-mutant NSCLC in South Korea. However, many patients experience peripheral neuropathy, which causes severe numbness, tingling, or painful muscle cramps. This side effect significantly lowers patients' quality of life and often leads to treatment interruptions. This phase 2, open-label, randomized clinical trial newly diagnosed EGFR mutant NSCLC patients is based on the hypothesis that a lower dose of lazertinib combined with magnesium supplementation will result in a more tolerable safety profile without compromising efficacy outcomes

Conditions

  • Non-small Cell Lung Cancer(NSCLC)
  • EGFR Mutant

Interventions

  • Supplementation of magnesium lactateDrug

    Supplementation of magnesium lactate

  • Dose reduction of lezertinibDrug

    Dose reduction of lazertinib 240mg to 160mg qd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference of grade 2 or higher peripheral neuropathyTime frame: From date of randomization until the date of first documented progression or date of death from any cause, or onset of peripheral neuropathy assessed up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Gang-nam Gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.